Aurobindo Pharma Limited
2,972words
0turns
0analyst exchanges
0executives
Key numbers — 40 extracted
rs,
ny Code No. AUROPHARMA To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804 Dear Sir / Madam, Sub: Inve
₹ 8,853
ncial Highlights 4 Key Financial Highlights of the Quarter Revenue EBITDA Net Profit Q4FY26 ₹ 8,853 Cr ₹ 1,801 Cr ₹ 921 Cr Q4FY25 ₹ 8,382 Cr ₹ 1,792 Cr ₹ 903 Cr Y-o-Y growth % 5.6% 0.5% 2.0%
₹ 1,801
ghts 4 Key Financial Highlights of the Quarter Revenue EBITDA Net Profit Q4FY26 ₹ 8,853 Cr ₹ 1,801 Cr ₹ 921 Cr Q4FY25 ₹ 8,382 Cr ₹ 1,792 Cr ₹ 903 Cr Y-o-Y growth % 5.6% 0.5% 2.0% 5 5 Busi
₹ 921
Financial Highlights of the Quarter Revenue EBITDA Net Profit Q4FY26 ₹ 8,853 Cr ₹ 1,801 Cr ₹ 921 Cr Q4FY25 ₹ 8,382 Cr ₹ 1,792 Cr ₹ 903 Cr Y-o-Y growth % 5.6% 0.5% 2.0% 5 5 Business Highl
₹ 8,382
hts of the Quarter Revenue EBITDA Net Profit Q4FY26 ₹ 8,853 Cr ₹ 1,801 Cr ₹ 921 Cr Q4FY25 ₹ 8,382 Cr ₹ 1,792 Cr ₹ 903 Cr Y-o-Y growth % 5.6% 0.5% 2.0% 5 5 Business Highlights – Q4FY26 Reve
₹ 1,792
uarter Revenue EBITDA Net Profit Q4FY26 ₹ 8,853 Cr ₹ 1,801 Cr ₹ 921 Cr Q4FY25 ₹ 8,382 Cr ₹ 1,792 Cr ₹ 903 Cr Y-o-Y growth % 5.6% 0.5% 2.0% 5 5 Business Highlights – Q4FY26 Revenue of ₹8,85
₹ 903
nue EBITDA Net Profit Q4FY26 ₹ 8,853 Cr ₹ 1,801 Cr ₹ 921 Cr Q4FY25 ₹ 8,382 Cr ₹ 1,792 Cr ₹ 903 Cr Y-o-Y growth % 5.6% 0.5% 2.0% 5 5 Business Highlights – Q4FY26 Revenue of ₹8,853 crores w
5.6%
Q4FY26 ₹ 8,853 Cr ₹ 1,801 Cr ₹ 921 Cr Q4FY25 ₹ 8,382 Cr ₹ 1,792 Cr ₹ 903 Cr Y-o-Y growth % 5.6% 0.5% 2.0% 5 5 Business Highlights – Q4FY26 Revenue of ₹8,853 crores with 5.6% growth YoY, dri
0.5%
₹ 8,853 Cr ₹ 1,801 Cr ₹ 921 Cr Q4FY25 ₹ 8,382 Cr ₹ 1,792 Cr ₹ 903 Cr Y-o-Y growth % 5.6% 0.5% 2.0% 5 5 Business Highlights – Q4FY26 Revenue of ₹8,853 crores with 5.6% growth YoY, driven by
2.0%
853 Cr ₹ 1,801 Cr ₹ 921 Cr Q4FY25 ₹ 8,382 Cr ₹ 1,792 Cr ₹ 903 Cr Y-o-Y growth % 5.6% 0.5% 2.0% 5 5 Business Highlights – Q4FY26 Revenue of ₹8,853 crores with 5.6% growth YoY, driven by stron
₹8,853 crore
,792 Cr ₹ 903 Cr Y-o-Y growth % 5.6% 0.5% 2.0% 5 5 Business Highlights – Q4FY26 Revenue of ₹8,853 crores with 5.6% growth YoY, driven by strong Europe performance coupled with stable US performance desp
₹1,801 crore
ormance coupled with stable US performance despite no transient product sales Reported EBITDA of ₹1,801 crores with a margin of 20.3%, driven by stable gross margins and operating efficiencies Net Capex of U